Nuclear functions ErbB380kDa and resistance to anti-tumor therapies prostate cancer

El Maassarani M.; Barbarin A.; Fromont G.Lebbe M.Moussa A.Vannier B.Seite P.

首页> 外文期刊>Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer >Nuclear functions ErbB380kDa and resistance to anti-tumor therapies prostate cancer

【24h】

Nuclear functions ErbB380kDa and resistance to anti-tumor therapies prostate cancer

机译：核函数ErbB380kDa和阻力抗肿瘤治疗前列腺癌

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer》 |2015年第6期|S123-S123|共1页
作者
El Maassarani M.; Barbarin A.; Fromont G.Lebbe M.Moussa A.Vannier B.Seite P.;
展开▼
作者单位

Abdelmalek Essaadi Univ, LabTIC Lab, ENSAT, Tanger, Morocco;

Univ Poitiers, Equipe 2RCT, Univ Poitiers SFA PBS 2RCT, F-86073 Poitiers 09, France;

CHU Poitiers, Lab Anat & Cytol Pathol, F-86000 Poitiers, France;

展开▼
收录信息
原文格式 PDF
正文语种法语
中图分类
关键词
Prostate Cancer; Atomic nuclei;

机译：前列腺癌;原子核;

相似文献

外文文献
中文文献
专利

1. Metastatic Prostate Cancer under Androgen Deprivation Therapy: Factors Influencing Castration Resistance [J] . Modou Ndiaye, Ousmane Sow, Babacar Sine, 泌尿学期刊（英文） . 2020,第007期
2. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance [J] . Merritt P Edlind, Andrew C Hsieh 亚洲男性学杂志（英文版） . 2014,第3期
3. Erratum to “Pre-existing Castration-resistant Prostate Cancer–like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy” Eur Urol 2022;81(5):446–55 (European Urology (2022) 81(5) (446–455), (S030228382200001X), (10.1016/j.eururo.2021.12.039)) [J] . Cheng Q., Butler W., Zhou Y.Zhang H.Tang L.Perkinson K.Chen X.Jiang X.?.McCall S.J.Inman B.A.Huang J. European urology . 2023,第6期

机译：Erratum to “Pre-existing Castration-resistant Prostate Cancer–like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy” Eur Urol 2022;81(5):446–55 (European Urology (2022) 81(5) (446–455), (S030228382200001X), (10.1016/j.eururo.2021.12.039))
4. Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance [J] . Luca Triggiani, Rosario Mazzola, DavideTomasiniAlessio BruniGiulia AlicinoFabio MatroneRoberto BortolusGiulio FrancoliniBeatrice DettiAlessro MagliMarco Lorenzo Bonù Medical oncology. . 2021,第6期

机译：Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance
5. Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in response to Onal's letter to the editor [J] . L. Triggiani, . Tomasini, R. Mazzola2 Medical oncology. . 2021,第11期

机译：Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in response to Onal's letter to the editor
6. CANCER THERAPY Tumours switch to resist [O] . ANTONI RIBAS, PAUL C. TUMEH -1

机译：CaNCER THERapY肿瘤切换到抗蚀剂
7. Mathematical Models of Androgen Resistance in Prostate Cancer Patients under Intermittent Androgen Suppression Therapy [O] . 2016

机译：mathematical models of androgen Resistance in prostate Cancer patients under Intermittent androgen suppression Therapy

Nuclear functions ErbB380kDa and resistance to anti-tumor therapies prostate cancer

著录项

相似文献

相关主题

期刊订阅